A Phase 3 interventional study of SPI-2012 and Pegfilgrastim in Neutropenia and Breast Cancer, sponsored by Spectrum Pharmaceuticals, Inc. Completed at 74 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.
Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing pegfilgrastim in Neutropenia — none open to participants now, none under way, none of them phase 3. pegfilgrastim · Neutropenia.
Among the 33 studies testing pegfilgrastim in Neutropenia, this one is the 8th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2017, is one of 11 in phase 3, and was the 31st registered.
316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.
Browse Neutropenia studies →None of the 33 studies testing pegfilgrastim in Neutropenia is open now. The open studies under Neutropenia, anywhere →
pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 237 is above the median of 82 across 230 interventional studies indexed under Neutropenia.
Median enrollment 121 across the 28 interventional studies. Of the 28 that completed or were terminated, 5 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Spectrum Pharmaceuticals, Inc, one of the names counted as Zydus Lifesciences Limited. Under that name alone:
Spectrum Pharmaceuticals, Inc is the lead sponsor of 60 studies on the registry; 1 is open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 12 (67%) have results posted.
Zydus Lifesciences Limited has 4 studies filed under Neutropenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing pegfilgrastim in Neutropenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia (DSN).
This is a Phase 3, randomized, open-label, active-controlled, multicenter study to compare the efficacy and safety of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer treated with TC chemotherapy as measured by the duration of severe neutropenia (DSN).
Each cycle was 21 days. Four cycles were evaluated for this study. On Day 1 of each cycle, participants received TC chemotherapy. On Day 2 of each cycle, participants received study drug (SPI-2012 or pegfilgrastim).
After cycle 1, as applicable, participants who received at least one dose of study drug will be followed for safety for 12 months after the last dose of study treatment.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At each cycle for 4 cycles, participants received SPI-2012 at a fixed dose of 13.2 milligrams (mg)/0.6 milliliter (mL), \[3.6 mg granulocyte colony-stimulating factor {G-CSF}\] subcutaneously (SC) approximately 24-26 hours after receiving intravenous (IV) infusion of docetaxel 75 mg/m\^2 and cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.
Drug: SPI-2012 · Drug: Docetaxel · Drug: Cyclophosphamide
At each cycle for 4 cycles, participants received pegfilgrastim 6 mg (6 mg/0.6 mL GCSF) SC approximately 24-26 hours after receiving IV infusion of docetaxel 75 mg/m\^2 and cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.
Drug: Pegfilgrastim · Drug: Docetaxel · Drug: Cyclophosphamide
Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
Also known as: HM10460A, Rolontis®, Eflapegrastim
Subcutaneous injection administered on Day 2 of each cycle.
Also known as: Neulasta®
75mg/m\^2 IV infusion administered on Day 1 of each cycle
Also known as: Taxotere
600mg/m\^2 IV infusion administered on Day 1 of each cycle
Also known as: Cytoxan
Duration of Severe Neutropenia (DSN) in Cycle 1
DSN was defined as the number of days of severe neutropenia (absolute neutrophil count \[ANC\] \<0.5×10\^9 per liter \[L\]) from the first occurrence of ANC below the threshold.
Time frame: Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)
Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 1
Time to ANC recovery was defined as the time from chemotherapy administration until the participants ANC increased to \>=1.5×10\^9/L after the expected nadir. For participants with ANC value \>=1.5×10\^9/L at all times, time to ANC Recovery was assigned a value of 0.
Time frame: Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)
Depth of ANC Nadir in Cycle 1
The depth of ANC Nadir was defined as the lowest ANC value after administration of study drug (SPI-2012 or pegfilgrastim) in Cycle 1.
Time frame: Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)
Number of Participants With Febrile Neutropenia (FN) in Cycle 1
FN was defined as an oral temperature \>38.3 degree Celsius (°C) (101.0 degrees Fahrenheit \[°F\]) or two consecutive readings of \>38.0°C (100.4°F) for 2 hours and ANC \<1.0×10\^9/L.
Time frame: Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)
Duration of Severe Neutropenia (DSN) in Cycles 2, 3 and 4
DSN was defined as the number of days of severe neutropenia (ANC \<0.5×10\^9/L) from the first occurrence of ANC below the threshold.
Time frame: Days 1, 4, 7, 10, and 15 of Cycles 2, 3, and 4 (each cycle = 21 days)
Number of Participants With Neutropenic Complications in Cycle 1
Neutropenic complications refer to hospitalizations due to neutropenic events and/or the use of anti-infectives due to neutropenia.
Time frame: Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)
Number of Participants With Febrile Neutropenia in Cycles 2, 3 and 4
FN was defined as an oral temperature \>38.3°C (101.0°F) or two consecutive readings of \>38.0°C (100.4°F) for 2 hours and ANC \<1.0×10\^9/L.
Time frame: Days 1, 4, 7, 10, and 15 of Cycles 2, 3, and 4 (each cycle = 21 days)
Relative Dose Intensity (RDI) of TC Chemotherapy
RDI was defined as the percentage of the planned dose of TC chemotherapy that each participant actually received during the study, and is expressed as the total dose received, divided by total dose planned multiplied by 100. The planned dose was defined as the dose that would be given if no doses were missed and/or no dose reductions were made for the number of cycles started. The total planned dose was the sum of planned doses over all cycles.
Time frame: Cycles 1, 2, 3 and 4 (each cycle = 21 days)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), and Death
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product or study procedure, whether or not considered related to the medicinal product. A TEAE is any AE that occurred from the first dose of study treatment through 12 months after the last dose of study treatment or 35 (±5) days after date of participant early discontinuation. SAE is defined as any AE which meets any of the following criteria: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, includes important medical events.
Time frame: Up to 4 cycles (each cycle = 21 days) plus a 12-month follow-up from the last dose (up to 15 months)
Number of Participants With Clinically Significant Laboratory Abnormalities
The number of participants with clinically significant hematology (including basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, hematocrit, hemoglobin, lymphocytes, lymphocytes/leukocytes, monocytes, monocytes/leukocytes, neutrophils, neutrophils/leukocytes, platelets, and white blood cells) and serum chemistry (including alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin, calcium, cholesterol, creatinine, potassium, sodium, and triglycerides) laboratory abnormalities were reported. Clinically significant findings in laboratory parameters were based on investigator's discretion according to Common Technical Criteria for Adverse Events (CTCAE) Version 4.03.
Time frame: Up to 4 cycles (each cycle = 21 days) plus a 12-month follow-up from the last dose (up to 15 months)
This study was conducted at 74 sites in the United States, Canada, Hungary, Poland, India, Korea from 10 May 2017 to 06 May 2019. The study was conducted in two periods: treatment period (first dose of TC until 35 (± 5) days after last dose of treatment) and safety follow-up period (End of Treatment Visit through 12 months after last dose of study treatment).
| Milestone | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC |
|---|---|---|
| Started | 118 | 119 |
| Safety population | 117 | 118 |
| Entered safety follow-up period | 117 | 118 |
| Completed | 96 | 85 |
| Not completed | 22 | 34 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Investigator decision | 3 | 3 |
| Withdrew: Initiated non-protocol therapy | 5 | 14 |
| Withdrew: Myeloid growth factors treatment | 0 | 1 |
| Withdrew: Withdrawal by subject | 9 | 9 |
| Withdrew: Sponsor decision | 0 | 2 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Reason not specified | 2 | 2 |
DSN was defined as the number of days of severe neutropenia (absolute neutrophil count \[ANC\] \<0.5×10\^9 per liter \[L\]) from the first occurrence of ANC below the threshold.
| Days | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC |
|---|---|---|
| Duration of Severe Neutropenia (DSN) in Cycle 1 | 0.31 ± 0.688 | 0.39 ± 0.949 |
Time to ANC recovery was defined as the time from chemotherapy administration until the participants ANC increased to \>=1.5×10\^9/L after the expected nadir. For participants with ANC value \>=1.5×10\^9/L at all times, time to ANC Recovery was assigned a value of 0.
| Days | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC |
|---|---|---|
| Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 1 | 3.49 ± 3.723 | 3.35 ± 3.745 |
The depth of ANC Nadir was defined as the lowest ANC value after administration of study drug (SPI-2012 or pegfilgrastim) in Cycle 1.
| 10^9 cells/L | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC |
|---|---|---|
| Depth of ANC Nadir in Cycle 1 | 2.67 ± 3.504 | 2.06 ± 2.034 |
FN was defined as an oral temperature \>38.3 degree Celsius (°C) (101.0 degrees Fahrenheit \[°F\]) or two consecutive readings of \>38.0°C (100.4°F) for 2 hours and ANC \<1.0×10\^9/L.
| Participants | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC |
|---|---|---|
| Number of Participants With Febrile Neutropenia (FN) in Cycle 1 | 1 | 4 |
DSN was defined as the number of days of severe neutropenia (ANC \<0.5×10\^9/L) from the first occurrence of ANC below the threshold.
| Days | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC |
|---|---|---|
| Cycle 2 | 0.08 ± 0.267 | 0.09 ± 0.432 |
| Cycle 3 | 0.07 ± 0.252 | 0.07 ± 0.283 |
| Cycle 4 | 0.07 ± 0.252 | 0.08 ± 0.266 |
Neutropenic complications refer to hospitalizations due to neutropenic events and/or the use of anti-infectives due to neutropenia.
| Participants | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC |
|---|---|---|
| Number of Participants With Neutropenic Complications in Cycle 1 | 1 | 5 |
FN was defined as an oral temperature \>38.3°C (101.0°F) or two consecutive readings of \>38.0°C (100.4°F) for 2 hours and ANC \<1.0×10\^9/L.
| Participants | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC |
|---|---|---|
| Cycle 2 | 0 | 2 |
| Cycle 3 | 0 | 0 |
| Cycle 4 | 0 | 0 |
RDI was defined as the percentage of the planned dose of TC chemotherapy that each participant actually received during the study, and is expressed as the total dose received, divided by total dose planned multiplied by 100. The planned dose was defined as the dose that would be given if no doses were missed and/or no dose reductions were made for the number of cycles started. The total planned dose was the sum of planned doses over all cycles.
| Percentage of planned dose | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC |
|---|---|---|
| Docetaxel | 96.9 ± 7.70 | 98.4 ± 7.89 |
| Cyclophosphamide | 98.4 ± 5.27 | 98.8 ± 6.40 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product or study procedure, whether or not considered related to the medicinal product. A TEAE is any AE that occurred from the first dose of study treatment through 12 months after the last dose of study treatment or 35 (±5) days after date of participant early discontinuation. SAE is defined as any AE which meets any of the following criteria: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, includes important medical events.
| Participants | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC | (Arm 1): SPI-2012 and TC: Follow-up Period | Arm 2: Pegfilgrastim and TC: Follow-up Period |
|---|---|---|---|---|
| TEAEs | 115 | 116 | 33 | 48 |
| SAEs | 12 | 19 | 2 | 4 |
| Death | 0 | 1 | 0 | 0 |
The number of participants with clinically significant hematology (including basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, hematocrit, hemoglobin, lymphocytes, lymphocytes/leukocytes, monocytes, monocytes/leukocytes, neutrophils, neutrophils/leukocytes, platelets, and white blood cells) and serum chemistry (including alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin, calcium, cholesterol, creatinine, potassium, sodium, and triglycerides) laboratory abnormalities were reported. Clinically significant findings in laboratory parameters were based on investigator's discretion according to Common Technical Criteria for Adverse Events (CTCAE) Version 4.03.
| Participants | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC |
|---|---|---|
| Hematology: Basophils | 0 | 0 |
| Hematology: Basophils/Leukocytes | 0 | 0 |
| Hematology: Eosinophils | 0 | 0 |
| Hematology: Eosinophils/Leukocytes | 0 | 0 |
| Hematology: Hematocrit | 4 | 2 |
| Hematology: Hemoglobin | 6 | 4 |
| Hematology: Lymphocytes | 0 | 0 |
| Hematology: Lymphocytes/Leukocytes | 6 | 13 |
| Hematology: Monocytes | 0 | 0 |
| Hematology: Monocytes/Leukocytes | 0 | 0 |
| Hematology: Neutrophils | 17 | 23 |
| Hematology: Neutrophils/Leukocytes | 12 | 9 |
| Hematology: Platelets | 10 | 2 |
| Hematology: White Blood Cells | 16 | 18 |
| Chemistry: Alanine aminotransferase | 2 | 1 |
| Chemistry: Alkaline phosphatase | 0 | 1 |
| Chemistry: Aspartate aminotransferase | 1 | 1 |
| Chemistry: Bilirubin | 0 | 0 |
| Chemistry: Calcium | 1 | 1 |
| Chemistry: Cholesterol | 0 | 0 |
| Chemistry: Creatinine | 0 | 0 |
| Chemistry: Potassium | 0 | 1 |
| Chemistry: Sodium | 0 | 2 |
| Chemistry: Triglycerides | 0 | 0 |
Collected over Up to 4 cycles (each cycle = 21 days) plus a 12-month follow-up from the last dose (up to 15 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| (Arm 1): SPI-2012 and TC | 0/117 (0%) | 12/117 (10.3%) | 115/117 (98.3%) |
| (Arm 2): Pegfilgrastim and TC | 1/118 (0.8%) | 19/118 (16.1%) | 116/118 (98.3%) |
| (Arm 1): SPI-2012 and TC: Follow-up Period | 0/117 (0%) | 2/117 (1.7%) | 33/117 (28.2%) |
| (Arm 2): Pegfilgrastim and TC: Follow-up Period | 0/118 (0%) | 4/118 (3.4%) | 48/118 (40.7%) |
| Event | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC | (Arm 1): SPI-2012 and TC: Follow-up Period | (Arm 2): Pegfilgrastim and TC: Follow-up Period |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/117 | 3/118 | 0/117 | 0/118 |
| FallInjury, poisoning and procedural complications | 2/117 | 0/118 | 0/117 | 0/118 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/117 | 2/118 | 0/117 | 0/118 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/117 | 2/118 | 0/117 | 0/118 |
| PneumoniaInfections and infestations | 0/117 | 2/118 | 0/117 | 0/118 |
| Chest painGeneral disorders | 1/117 | 1/118 | 0/117 | 0/118 |
| PyrexiaGeneral disorders | 1/117 | 1/118 | 0/117 | 0/118 |
| Supraventricular tachycardiaCardiac disorders | 1/117 | 0/118 | 0/117 | 0/118 |
| Cardiac arrestCardiac disorders | 0/117 | 0/118 | 1/117 | 0/118 |
| Myocardial infarctionCardiac disorders | 0/117 | 0/118 | 1/117 | 0/118 |
| Event | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC | (Arm 1): SPI-2012 and TC: Follow-up Period | (Arm 2): Pegfilgrastim and TC: Follow-up Period |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 50/117 | 61/118 | 1/117 | 1/118 |
| Lymphocyte count decreasedInvestigations | 44/117 | 54/118 | 0/117 | 1/118 |
| FatigueGeneral disorders | 40/117 | 51/118 | 0/117 | 0/118 |
| Bone painMusculoskeletal and connective tissue disorders | 47/117 | 51/118 | 1/117 | 1/118 |
| AlopeciaSkin and subcutaneous tissue disorders | 40/117 | 43/118 | 1/117 | 0/118 |
| DiarrhoeaGastrointestinal disorders | 38/117 | 40/118 | 1/117 | 3/118 |
| NeutropeniaBlood and lymphatic system disorders | 37/117 | 37/118 | 0/117 | 0/118 |
| HeadacheNervous system disorders | 31/117 | 35/118 | 0/117 | 1/118 |
| White blood cell count decreasedInvestigations | 22/117 | 31/118 | 1/117 | 2/118 |
| ConstipationGastrointestinal disorders | 26/117 | 24/118 | 0/117 | 2/118 |
Intent-to-Treat (ITT) Population includes all participants who were randomized.
| Age, Continuous(years) | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC | Total |
|---|---|---|---|
| Mean | 57.9 ± 11.27 | 58.1 ± 12.67 | 58.0 ± 11.97 |
| Sex: Female, Male(Participants) | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC | Total |
|---|---|---|---|
| Female | 118 | 119 | 237 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 15 | 33 |
| Not Hispanic or Latino | 100 | 104 | 204 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | (Arm 1): SPI-2012 and TC | (Arm 2): Pegfilgrastim and TC | Total |
|---|---|---|---|
| White or Caucasian | 85 | 96 | 181 |
| Black or African American | 11 | 7 | 18 |
| Asian | 20 | 16 | 36 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Other | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Jun 2018, 12 months.
Results were first posted in Mar 2022, 3 years 8 months after primary completion. A results delay was requested in Jan 2020.
Of 16 phase 3 interventional studies under Neutropenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Eflapegrastim · Pegfilgrastim
Spectrum Pharmaceuticals, Inc →